Bioadaptives Stock Performance
| BDPT Stock | USD 0.10 0.07 233.33% |
BioAdaptives holds a performance score of 11 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -134.99, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning BioAdaptives are expected to decrease by larger amounts. On the other hand, during market turmoil, BioAdaptives is expected to outperform it. Use BioAdaptives treynor ratio and the relationship between the semi variance and price action indicator , to analyze future returns on BioAdaptives.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in BioAdaptives are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, BioAdaptives unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 4587.00 |
BioAdaptives |
BioAdaptives Relative Risk vs. Return Landscape
If you would invest 0.07 in BioAdaptives on August 27, 2024 and sell it today you would earn a total of 9.93 from holding BioAdaptives or generate 14185.71% return on investment over 90 days. BioAdaptives is currently generating 19.4513% in daily expected returns and assumes 130.745% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than BioAdaptives, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioAdaptives Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioAdaptives' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as BioAdaptives, and traders can use it to determine the average amount a BioAdaptives' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1488
| Best Portfolio | Best Equity | BDPT | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 130.75 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average BioAdaptives is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioAdaptives by adding it to a well-diversified portfolio.
BioAdaptives Fundamentals Growth
BioAdaptives Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BioAdaptives, and BioAdaptives fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioAdaptives Pink Sheet performance.
| Return On Asset | -3.43 | |||
| Operating Margin | (33.58) % | |||
| Current Valuation | 544.74 K | |||
| Shares Outstanding | 160.49 M | |||
| Price To Earning | (14.28) X | |||
| Price To Sales | 7.53 X | |||
| Revenue | 19.78 K | |||
| EBITDA | (643.76 K) | |||
| Cash And Equivalents | 49.58 K | |||
| Total Debt | 450.26 K | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (158.65 K) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 148.59 K | |||
| Retained Earnings | (2.96 M) | |||
| Current Asset | 156 K | |||
| Current Liabilities | 316 K | |||
About BioAdaptives Performance
Assessing BioAdaptives' fundamental ratios provides investors with valuable insights into BioAdaptives' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the BioAdaptives is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
BioAdaptives, Inc. markets and distributes natural plant and algal-based products for humans and animals. BioAdaptives, Inc. was incorporated in 2013 and is based in Las Vegas, Nevada. Bioadaptives operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 3 people.Things to note about BioAdaptives performance evaluation
Checking the ongoing alerts about BioAdaptives for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for BioAdaptives help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioAdaptives is way too risky over 90 days horizon | |
| BioAdaptives has some characteristics of a very speculative penny stock | |
| BioAdaptives appears to be risky and price may revert if volatility continues | |
| BioAdaptives has high likelihood to experience some financial distress in the next 2 years | |
| BioAdaptives currently holds 450.26 K in liabilities. BioAdaptives has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist BioAdaptives until it has trouble settling it off, either with new capital or with free cash flow. So, BioAdaptives' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioAdaptives sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioAdaptives to invest in growth at high rates of return. When we think about BioAdaptives' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 19.78 K. Net Loss for the year was (1.05 M) with profit before overhead, payroll, taxes, and interest of 10.11 K. | |
| BioAdaptives currently holds about 49.58 K in cash with (158.65 K) of positive cash flow from operations. |
- Analyzing BioAdaptives' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioAdaptives' stock is overvalued or undervalued compared to its peers.
- Examining BioAdaptives' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioAdaptives' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioAdaptives' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioAdaptives' pink sheet. These opinions can provide insight into BioAdaptives' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioAdaptives Pink Sheet Analysis
When running BioAdaptives' price analysis, check to measure BioAdaptives' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAdaptives is operating at the current time. Most of BioAdaptives' value examination focuses on studying past and present price action to predict the probability of BioAdaptives' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAdaptives' price. Additionally, you may evaluate how the addition of BioAdaptives to your portfolios can decrease your overall portfolio volatility.